Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

ClinicalTrials.gov ID: NCT06626919

Public ClinicalTrials.gov record NCT06626919. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-Oncology Plasma Cell-Related Diseases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG.

Study identification

NCT ID: NCT06626919
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Kite, A Gilead Company; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2025 (Actual)
Primary completion: Oct 2028 (Estimated)
Completion: Oct 2028 (Estimated)
Last update posted: Oct 22, 2026

2025 – 2028

United States locations

U.S. sites: 14
U.S. states: 9
U.S. cities: 13

Facility	City	State	ZIP	Site status
Ronald Reagan UCLA Medical Center	Los Angeles	California	90095	Recruiting
UC Irvine Medical Center	Orange	California	92868	Recruiting
Stanford Blood and Marrow Transplant	Palo Alto	California	94305	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare	Tampa	Florida	33612	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
University of Minnesota Delaware Clinical Research Unit	Minneapolis	Minnesota	55455	Recruiting
Mayo Clinic	Rochester	Minnesota	55902	Recruiting
Columbia University Irving Medical Center	New York	New York	10032	Recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	Recruiting
Oregon Health & Science University	Portland	Oregon	97239	Recruiting
Lewis Katz School of Medicine at Temple University	Philadelphia	Pennsylvania	19140	Recruiting
UT Southwestern Medical Center	Dallas	Texas	75390	Recruiting
Houston Methodist Hospital	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06626919, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 22, 2026 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06626919 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →